Molecular Pathogenesis and Current Treatment Landscape In MPN, With A Focus On PV

01 Nov 2022
Molecular Pathogenesis and Current Treatment Landscape In MPN, With A Focus On PV
The recent Northern Haematology Update, held in Penang, saw Dr Christopher Ng, Dr Tan Sui Keat and Dr Carol Goh present on various aspects of myeloproliferative neoplasms (MPN)and its management. Dr Christopher Ng, a haematology trainee at Hospital Sultanah Bahiyah, Kedah, discussed the role of mutations as drivers of disease, with a focus on polycythaemiavera (PV) and essential thrombocythaemia (ET).
Sponsored as an educational program by Novartis Corporation (Malaysia) Sdn Bhd

Related MIMS Drugs

Resources

MY-NOV-308

MY-NOV-308

MY-NOV-308

MY-NOV-308